Pure Global
NCT05736081

Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Asociación para Evitar la Ceguera en México·Phase 2/3·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
Intravitreal dexamethasone implant
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Asociación para Evitar la Ceguera en México
Location
Mexico city, Mexico
Timeline & enrollment
Phase
Phase 2/3
Start date
Feb 15, 2018
End date
Jun 30, 2019
Enrollment
15 participants
Primary outcome

Change in central retinal thickness

Summary

The goal of this clinical trial es to learn about the short term effects of intravitreal
 dexamethasone implant (IDI) in patients with refractory diabetic macular edema. The main
 question it aims to answer is:
 
 How fast does the diminishing in central retinal thickness has statistical significance after
 IDI in patients with refractory diabetic macular edema? Patients will be evaluated by OCT
 before and after the implant.

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05736081
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05736081 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Asociación para Evitar la Ceguera en México and is currently Completed. The study focuses on Diabetic Macular Edema. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.